OBJECTIVES: Bleeding is the most common non-ischemic complication in patients with coronary revascularisation procedures, associated with prolonged hospitalisation and increased mortality. Many factors predispose for bleeds in these patients, among those sex. Anyhow, few studies have characterised the population receiving triple antithrombotic therapy (TAT) as well as long term bleeds from a sex perspective. We investigated the one year rate of bleeds in patients receiving TAT, potential sex disparities and premature discontinuation of TAT. We also assessed health care costs in bleeders vs non-bleeders. SETTING: Three hospitals in the County of Östergötland, Sweden during 2009-2015. PARTICIPANTS: All patients discharged with TAT registered in the SWEDEHEART registry. PRIMARY AND SECONDARY OUTCOME MEASURES: All bleeds receiving medical attention during one-year follow-up were collected by retrieving relevant information about each patient from medical records. Resource use associated with bleeds was assigned unit cost to estimate the health care costs associated with bleeding episodes. RESULTS: Among 272 patients, 156 bleeds occurred post-discharge, of which 28.8% were gastrointestinal. In total 54.4% had at least one bleed during or after the index event and 40.1% bled post discharge of whom 28.7% experienced a TIMI major or minor bleeding. Women discontinued TAT prematurely more often than men (52.9 vs 36.1%, p = 0.01) and bled more (48.6 vs. 37.1%, p = 0.09). One-year mean health care costs were EUR 575 and EUR 5787 in non-bleeding and bleeding patients, respectively. CONCLUSION: The high bleeding incidence in patients with TAT, especially in women, is a cause of concern. There is a need for an adequately sized randomised, controlled trial to determine a safe but still effective treatment for these patients.
OBJECTIVES:Bleeding is the most common non-ischemic complication in patients with coronary revascularisation procedures, associated with prolonged hospitalisation and increased mortality. Many factors predispose for bleeds in these patients, among those sex. Anyhow, few studies have characterised the population receiving triple antithrombotic therapy (TAT) as well as long term bleeds from a sex perspective. We investigated the one year rate of bleeds in patients receiving TAT, potential sex disparities and premature discontinuation of TAT. We also assessed health care costs in bleeders vs non-bleeders. SETTING: Three hospitals in the County of Östergötland, Sweden during 2009-2015. PARTICIPANTS: Allpatients discharged with TAT registered in the SWEDEHEART registry. PRIMARY AND SECONDARY OUTCOME MEASURES: Allbleeds receiving medical attention during one-year follow-up were collected by retrieving relevant information about each patient from medical records. Resource use associated with bleeds was assigned unit cost to estimate the health care costs associated with bleeding episodes. RESULTS: Among 272 patients, 156 bleeds occurred post-discharge, of which 28.8% were gastrointestinal. In total 54.4% had at least one bleed during or after the index event and 40.1% bled post discharge of whom 28.7% experienced a TIMI major or minor bleeding. Women discontinued TAT prematurely more often than men (52.9 vs 36.1%, p = 0.01) and bled more (48.6 vs. 37.1%, p = 0.09). One-year mean health care costs were EUR 575 and EUR 5787 in non-bleeding and bleedingpatients, respectively. CONCLUSION: The high bleeding incidence in patients with TAT, especially in women, is a cause of concern. There is a need for an adequately sized randomised, controlled trial to determine a safe but still effective treatment for these patients.
Authors: Dominick J Angiolillo; Shaun G Goodman; Deepak L Bhatt; John W Eikelboom; Matthew J Price; David J Moliterno; Christopher P Cannon; Jean-Francois Tanguay; Christopher B Granger; Laura Mauri; David R Holmes; C Michael Gibson; David P Faxon Journal: Circulation Date: 2018-07-31 Impact factor: 29.690
Authors: Juan Torrado; Leo Buckley; Ariel Durán; Pedro Trujillo; Stefano Toldo; Juan Valle Raleigh; Antonio Abbate; Giuseppe Biondi-Zoccai; Luis A Guzmán Journal: J Am Coll Cardiol Date: 2018-04-17 Impact factor: 24.094
Authors: Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine Journal: Eur Heart J Date: 2018-01-14 Impact factor: 29.983
Authors: Morten Lamberts; Gunnar H Gislason; Jonas Bjerring Olesen; Søren Lund Kristensen; Anne-Marie Schjerning Olsen; Anders Mikkelsen; Christine Benn Christensen; Gregory Y H Lip; Lars Køber; Christian Torp-Pedersen; Morten Lock Hansen Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook Journal: Circulation Date: 1987-07 Impact factor: 29.690
Authors: Konstantinos C Koskinas; Lorenz Räber; Thomas Zanchin; Peter Wenaweser; Stefan Stortecky; Aris Moschovitis; Ahmed A Khattab; Thomas Pilgrim; Stefan Blöchlinger; Christina Moro; Peter Jüni; Bernhard Meier; Dik Heg; Stephan Windecker Journal: Circ Cardiovasc Interv Date: 2015-05 Impact factor: 6.546
Authors: Sunil V Rao; Kristi O'Grady; Karen S Pieper; Christopher B Granger; L Kristin Newby; Kenneth W Mahaffey; David J Moliterno; A Michael Lincoff; Paul W Armstrong; Frans Van de Werf; Robert M Califf; Robert A Harrington Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Connie N Hess; Eric D Peterson; S Andrew Peng; James A de Lemos; Emil L Fosbol; Laine Thomas; Deepak L Bhatt; Jorge F Saucedo; Tracy Y Wang Journal: J Am Coll Cardiol Date: 2015-08-11 Impact factor: 24.094